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Abstract
Fibroblast growth factor 23 (FGF23) circulates as active protein and inactive fragments. Low iron 
status increases FGF23 gene expression, and iron deficiency is common. We hypothesized that in 
healthy premenopausal women, serum iron influences C-terminal and intact FGF23 
concentrations, and that iron and FGF23 associate with bone mineral density (BMD).
Serum iron, iron binding capacity, percent iron saturation, phosphorus, and other biochemistries 
were measured in stored fasting samples from healthy premenopausal white (n=1898) and black 
women (n= 994), age 20–55 years. Serum C-terminal and intact FGF23 were measured in a subset 
(1631 white and 296 black women). BMD was measured at the lumbar spine and femur neck.
Serum phosphorus, calcium, alkaline phosphatase and creatinine were lower in white women than 
black women (p<0.001). Serum iron (p<0.0001) and intact FGF23 (p< 0.01) were higher in white 
women. C-terminal FGF23 did not differ between races. Phosphorus correlated with intact FGF23 
(white women, r=0.120, p<0.0001; black women r=0.163, p<0.01). However, phosphorus 
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correlated with C-terminal FGF23 only in black women (r=0.157, p<0.01). Intact FGF23 did not 
correlate with iron. C-terminal FGF23 correlated inversely with iron (white women r=−0.134, 
p<0.0001; black women r=−0.188, p<0.01), having a steeper slope at iron <50 mcg/dl than >50 
mcg/dl. Longitudinal changes in iron predicted changes in C-terminal FGF23.
Spine BMD correlated with iron negatively (r=−0.076, p<0.01) in white women; femur neck BMD 
correlated with iron negatively (r=−0.119, p<0.0001) in black women. Both relationships were 
eliminated in weight-adjusted models. BMD did not correlate with FGF23.
Serum iron did not relate to intact FGF23, but was inversely related to C-terminal FGF23. Intact 
FGF23 correlated with serum phosphorus. In weight-adjusted models, BMD was not related to 
intact FGF23, C-terminal FGF23 or iron. The influence of iron on FGF23 gene expression is not 
important in determining bone density in healthy premenopausal women.
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1. Introduction
Fibroblast growth factor 23 (FGF23) is a hormone produced in osteocytes, which in the renal 
tubule decreases expression of sodium phosphate co-transporters and of vitamin D 1α-
hydroxylase, thus decreasing phosphorus reabsorption and serum phosphorus and 1,25-
dihydroxyvitamin D [1,25(OH)2D] levels(1). High serum phosphorus and 1,25(OH)2D 
increase production of FGF23, providing regulation via a feedback loop. FGF23 is secreted 
both as inactive fragments and as active intact protein (2). Serum FGF23 is currently 
measured using two different assays: an assay detecting only the biologically active intact 
FGF23 (intact assay) and an assay that detects the combination of intact hormone plus 
biologically inactive C-terminal fragments (C-terminal assay)(3, 4). Disorders of increased 
intact FGF23 cause hypophosphatemic rickets/osteomalacia (5–7), while disorders of 
decreased intact FGF23 cause hyperphosphatemia with ectopic calcifications(2, 8). FGF23 
has been proposed also to directly impair skeletal mineralization, independent of 
hypophosphatemia(9). Studies on the influence of FGF23 on bone mineral density (BMD), 
independent of its effect on phosphorus and bone mineralization, have produced conflicting 
results. Studies investigating the relationships of FGF23 on BMD and/or fracture risk in 
post-menopausal women or older men have reported either a positive or no relationship 
between C-terminal or intact FGF23 and lumbar spine or proximal femur BMD (10–14).
In autosomal dominant hypophosphatemic rickets (ADHR), a genetic mutation causes 
FGF23 to resist proteolytic cleavage(15). Disease activity waxes and wanes, with high intact 
FGF23 and hypophosphatemia occurring during times of low serum iron concentrations (3, 
7). Low iron status increases FGF23 gene expression (3, 4), and in the absence of a 
mutation, intact FGF23 concentrations remain normal as measured by the intact assay, but 
C-terminal fragments increase as detected by the C-terminal assay (3, 4). Low iron status is 
associated with high incidence of stress fractures in females (16). On the other hand, iron 
overload, such as occurs in hemochromatosis, is associated with osteoporosis, even in the 
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absence of hypogonadism which commonly occurs in hemochromatosis(17). Furthermore, 
in post-menopausal women, higher quartiles of ferritin, a marker of higher iron stores, are 
associated with lower bone mineral density (BMD) and greater risk of vertebral fracture(18, 
19). The relationships among iron status, serum FGF23 levels and BMD in premenopausal 
women remain to be established.
If iron influences BMD, one possible mechanism could be through changes in serum intact 
FGF23 or its C-terminal fragments. We sought to test the following hypotheses in healthy 
premenopausal white and black women: 1) Serum iron concentration is negatively 
associated with both C-terminal and intact FGF23 concentrations; and 2) Serum iron and 
FGF23 concentrations are associated with BMD at the proximal femur and lumbar spine 
(L2–4) in both white and black women.
2. Materials and Methods
2.1 Subjects
Healthy premenopausal adult white and black women in Indiana were recruited into a study 
to discover genes and other predictors underlying peak bone mass(20). Serum iron and 
FGF23 concentrations and additional mineral metabolism biochemistries related to FGF23 
activity were measured in samples from 2,892 subjects, age 20–55 years. Both white women 
and black women were assessed due to racial differences in BMD. Due to cost, FGF23 was 
measured in a subset of white women who had been part of a previous GWAS(20). FGF23 
was measured in a subset of the black women to identify racial differences and validate the 
FGF23 iron relationships in black women. Serum samples from return visits (median 5.7 
years) (21) were available in 356 white women for measures of changes in iron and FGF23. 
This research was conducted in accordance with the Declaration of Helsinki. The protocol 
was approved by the Indiana University Institutional Review Board, and all subjects signed 
informed consent prior to participating.
2.2 Measurements
Fasting blood samples were collected in all subjects after an overnight fast and stored at 
−80° C until analysis. Serum biochemistries were measured with the Randox Daytona 
clinical chemistry analyzer (Randox Laboratories; Antrim, Northern Ireland, United 
Kingdom) for calcium, phosphorus, creatinine, total alkaline phosphatase, iron, and unbound 
iron binding capacity (UIBC). Iron and UIBC were measured using a spectrophotometric 
method. Total iron binding capacity (TIBC) was calculated as the sum of serum iron and 
UIBC. Iron saturation was calculated as serum iron ÷ TIBC and expressed as a percentage. 
Iron deficiency was defined as serum iron concentration < 50 mcg/dl (22). Parathyroid 
hormone (PTH), 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D [1,25(OH)2D] were 
measured using radioimmunoassays from DiaSorin (Stillwater, MN) in a subset of white 
women.
FGF23 was measured using two different ELISAs: the intact FGF23 ELISA from Kainos 
Laboratories (Tokyo, Japan), measured only intact (biologically active) FGF23; and the C-
terminal FGF23 ELISA (Immutopics, San Clemente, CA) measures a combination of both 
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C-terminal fragments and intact FGF23. The intra-assay and inter-assay coefficients of 
variation (CV) were 7.6% and 13.5% for C-terminal FGF23. The intra-assay and inter-assay 
CV were 6.7% and 4.4% for intact FGF23.
Areal BMD (g/cm2) at the lumbar spine (L2–L4) and femoral neck were measured by DXA, 
using two DPX-L and one Prodigy machines (GE Lunar Corp., Madison, WI, USA), which 
were cross-calibrated weekly with a step-wedge phantom. There were no systematic 
differences among the three devices. The CV of duplicate measurements after subject 
repositioning was 1.0% for femoral neck and 0.52% for lumbar spine. Height was measured 
using a Harpenden stadiometer and weight with a Scale-Tronix scale.
2.3 Statistical Analysis
All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC). Categorical 
variables were summarized by counts and percentages and were compared using Chi-square 
tests. Continuous variables were summarized by medians and 1st and 3rd quartiles. The ratio 
of intact FGF23 to C-terminal FGF23 was calculated to identify whether similar proportions 
of intact FGF23 and fragments occurred between black women and white women. Wilcoxon 
rank sum tests were used to compare variables between the two race groups, since normality 
assumptions were violated for most variables. Logarithmic transformations of base 10 were 
applied to both C-terminal and intact FGF23 before all analyses. Pearson’s correlation, 
Spearman’s correlation and scatter plots with linear fits were used to explore pair-wise 
relationships. Since Pearson’s and Spearman’s correlation gave similar results for this data 
set, Pearson’s correlations were presented to be consistent with the linear fits. Given that 
there were two major hypotheses with sub-hypotheses under each and relatively large 
sample sizes, as a conservative threshold, we adopted a Type I error level of 0.01 instead of 
the conventional 0.05 level.
The relationships between FGF23 and iron were evaluated using change-point models with 
the change-point at an iron concentration of 50 mcg/dl. These models allow the relationships 
between FGF23 and iron, i.e., the slopes of the linear regressions, to be different for iron 
<50 mcg/dl and for iron ≥50 mcg/dl as suggested by the exploratory plots. The models were 
adjusted for factors involved in iron metabolism, or bone and mineral metabolism, as well as 
race, age, height, weight. Since UIBC increases in the setting of iron deficiency (23, 24), 
UIBC was included in these models as a measure of iron binding capacity. UIBC was chosen 
because UIBC was directly measured, as opposed to TIBC or iron saturation, which were 
calculated based on serum iron and the UIBC. Two main adjusted regression models for the 
relationship between iron and FGF23 were used. Model 1 adjusted for race, age, height, 
weight, serum UIBC, phosphorus, calcium, creatinine, and alkaline phosphatase. Model 2 
was applied to only white women and adjusted for variables in Model 1, plus PTH, 25OHD 
and 1,25(OH)2D. The relationships between FGF23 and vitamin D metabolites (25OHD and 
1,25(OH)2D) were evaluated using partial correlations, adjusting for the other variables in 
Model 2 including iron. The relationships between longitudinal changes in iron and FGF23 
were evaluated by linear regression.
The BMD relationships with iron were first evaluated using bivariate linear regressions; 
while adjusting for age, race, height, weight, serum UIBC (Model A) and the addition of 
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intact and C-terminal FGF23 (Model B). Since weight interacted with serum iron 
concentration in the models for BMD, in Model C an interaction term between iron and 
obesity was added (BMI<30 vs ≥30 kg/m2) to the variables in Model B. Models D and E, 
applied to white women only, added PTH, 25OHD and 1,25(OH)2D to Models B and C, 
respectively. All models were examined separately for black and white women.
3. Results
3.1 Cohort description and biochemistries
Cohort characteristics and differences between the premenopausal white and black women 
are shown in Table 1. White women had lower weight and were taller. White women had 
lower median serum phosphorus, calcium, alkaline phosphatase and creatinine levels than 
black women, and higher iron, TIBC and iron saturation. More black women than white 
women had serum iron concentration <50 mcg/dl (26.5% versus 10.0%, respectively, 
p<0.0001). Serum PTH, 25OHD and 1,25(OH)2D3, measured in only white women, were 
normal. BMD at the femur neck and spine was lower in white women than in black women 
(p<0.0001).
Median serum intact FGF23 concentration was higher in white women than black women 
(p<0.01, Table 1), but median serum C-terminal FGF23 did not differ between groups. The 
median ratios of intact to C-terminal FGF23 did not differ between white women and black 
women. FGF23 values were log transformed for analyses. C-terminal FGF23 correlated 
positively with intact FGF23 in white women (r=0.122, p<0.0001), but not in black women 
(r=0.041, p=0.48). The slope for the line (y=log10[C-terminal FGF23], x=log10[intact 
FGF23]) was also numerically steeper (0.22) for white women than for black women (0.08), 
but the slopes were not significantly different (p=0.3).
In white women, phosphorus was positively related to intact FGF23 (r=0.120, p<0.0001) but 
not to C-terminal FGF23 (r=0.047, p=0.06). However, phosphorus was positively correlated 
with both intact FGF23 (r=0.163, p<0.01) and C-terminal FGF23 (r=0.157 p<0.01) in black 
women. Serum phosphorus was inversely related to serum iron concentration in both white 
women (r=−0.061, p<0.01) and black women (r=−0.113, p<0.001).
In white women, phosphorus correlated negatively with PTH (r=−0.099, p<0.01), but not 
with 1,25(OH)2D or 25OHD. PTH correlated negatively with 25OHD (r= −0.148, p<0.0001) 
but not with 1,25(OH)2D. PTH was not related to C-terminal FGF23 or intact FGF23. C-
terminal FGF23 correlated negatively with 25OHD (r=−0.105, p<0.001), but not with 
1,25(OH)2D (r= −0.044, p=0.2). However, intact FGF23 correlated negatively with 
1,25(OH)2D (r=−0.113, p<0.01), but not with 25OHD (r=0.043, p=0.17). Of note, iron 
weakly correlated with 25OHD (r=0.083, p<0.01), but not with 1,25(OH)2D (r=0.064, 
p=0.06).
Intact FGF23 correlated positively with weight to a similar degree in both groups (white 
women r= 0.109, p <0.001; black women r= 0.156, p <0.01). However, C-terminal FGF23 
inversely correlated with weight in black women (r= −0.151, p < 0.01) but not in white 
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women (p=0.9). Serum iron also inversely correlated with weight, similarly in white women 
(r=−0.197, p<0.0001) and black women (r=−0.210, p<0.0001).
3.2 FGF23 and Iron
Serum intact FGF23 concentration did not relate to iron in either white or black women 
(Figure 1). However, in both groups, serum C-terminal FGF23 concentration was related 
inversely to serum iron concentration (white women r= −0.134, p<0.0001; black women r= 
−0.188, p<0.01). UIBC correlated inversely with serum iron concentration similarly in white 
and black women (white women r=−0.483, p<0.0001; black women r=−0.557, p<0.0001). 
Consistent with this relationship, UIBC was positively correlated with C-terminal FGF23 
(white women r=0.105, p<0.0001; black women r=0.205, p<0.001), but not with intact 
FGF23. Whereas TIBC was not related to C-terminal or intact FGF23 in either group.
The relationship between C-terminal FGF23 and serum iron had a steeper slope at iron <50 
mcg/dl, the value taken as indicating iron deficiency, than at iron ≥50 mcg/dl (Figure 1 and 
Table 2). Incorporating a slope change-point for iron at 50 mcg/dl, the relationship of C-
terminal FGF23 to iron was not present when iron values were ≥50 mcg/dl, but was highly 
significantly negative when serum iron was <50 mcg/dl, in both white women (r=−0.284, 
p<0.0001) and black women (r=−0.299, p<0.001) (Table 2, Base Model). The slope was 
somewhat steeper when iron was <50 mcg/dl in white women than in black women (p=0.01 
for differences between race groups). When iron is <50 mcg/dl, a 10mcg/dl decrease in iron 
corresponded to approximately a 20% increase in C-terminal FGF23 in black women and a 
42% increase in C-terminal FGF23 in white women. These slopes remained similar in 
adjusted models, but the difference between groups lost significance (below). The 
relationship of iron to C-terminal FGF23 also varied according to serum phosphorus 
concentration (Supplemental Figure 1), such that high serum phosphorus decreased the 
relationship of iron with C-terminal FGF23.
3.3 Multivariable models for FGF23 and iron
In a multivariable regression model (Table 2, adjusted Model 1), the negative relationship of 
C-terminal FGF23 to iron when serum iron is <50 mcg/dl was significant (p<0.001) in both 
white women and black women after adjusting for race, age, height, weight, serum UIBC, 
phosphorus, calcium, creatinine and alkaline phosphatase. In this model age and serum 
phosphorus remained independently associated with C-terminal FGF23 (each p<0.01). 
Adjusted Model 2 was fitted in white women only, adding PTH, 25OHD, and 1,25(OH)2D 
to the variables in Model 1 (Table 2), as these variables were not measured in black women. 
In Model 2, C-terminal FGF23 remained significantly inversely related to iron <50 mcg/dl, 
without decrease in effect size (compared to the Base Model or to adjusted Model 1). In 
addition C-terminal FGF23 was now also inversely related to serum iron at iron 
concentrations ≥50 mcg/dl (p<0.01). In contrast, intact FGF23 was not significantly related 
to iron in similarly adjusted models.
3.4 Multivariable modeling for FGF23 and vitamin D
Using Pearson correlations, C-terminal FGF23 was negatively correlated to 25OHD, while 
intact FGF23 was negatively correlated to 1,25(OH)2D (see above). However, after adjusting 
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for iron and Model 2 variables, C-terminal FGF23 was no longer significantly related to 
either 25OHD or 1,25(OH)2D (p>0.4). In contrast, intact FGF23 remained significantly 
negatively related to 1,25(OH)2D (r=−0.092, p<0.01), and was now positively related to 
25OHD (r=0.124, p<0.01).
3.5 BMD relationship to iron and FGF23
Spine BMD was related inversely to serum iron (r= −0.076, p<0.01) only in white women; 
whereas femur neck BMD was related inversely to serum iron (r= −0.119, p<0.0001) only in 
black women (Figure 2). Similarly, spine BMD correlated inversely to percent iron 
saturation only in white women (p<0.01), while femur neck BMD correlated inversely to 
percent iron saturation only in black women (p<0.001) (Supplemental Table 1).
The relationships between FGF23 and BMD are shown in Figure 3. At the femur neck, 
BMD did not correlate significantly with intact FGF23 or C-terminal FGF23 in either white 
women or black women. Spine BMD did not correlate significantly with intact FGF23 in 
white women (r=0.037, p=0.16) or in black women (r= 0.149, p=0.011). There were no 
significant correlations between spine BMD and C-terminal FGF23.
Correlations between BMD and additional variables in white women and black women are 
shown in Supplemental Table 1. BMD at the femur neck correlated negatively with age 
(p<0.01) in white and black women, while spine BMD correlated positively with age in 
white women (p<0.0001). BMD at both the femur neck and spine correlated most strongly 
(and positively) with weight and height in white women and black women (p<0.0001). 
Femur neck BMD was related positively to serum phosphorus, creatinine, UIBC and TIBC 
(p<0.01) only in white women. Femur neck BMD correlated negatively to serum calcium in 
black women (p<0.01). Spine BMD did not correlate with phosphorus, UIBC, TIBC, 
creatinine or calcium in white women or black women. BMD did not correlate with alkaline 
phosphatase levels.
3.6 Multivariable models for BMD
Although there were negative correlations between BMD and serum iron on univariate 
analysis (at the femur neck for black women, and at the spine for white women; Figure 2), 
adjusting for race, age, height, weight and UIBC, eliminated these inverse relationships 
(Model A, Supplemental Table 2). After adding C-terminal and intact FGF23 to the model 
(Model B), femur neck BMD was now positively associated with serum iron (p<0.01) in 
white women, contrasting with the negative correlation in univariate analysis of black 
women. Spine BMD was not significantly related to serum iron in any of the adjusted 
models.
The loss of the negative relationship of BMD with iron in multivariate models was primarily 
due to weight. The associations of BMD with iron for obese (BMI≥30 kg/m2) and non-obese 
((BMI<30) subjects were assessed after adjusting for race, age, height, weight, UIBC, C-
terminal FGF23 and intact FGF23 (Model C, Supplemental Table 2). Model C indicated no 
relationships between BMD and iron, except a small positive association remaining between 
femur neck BMD and iron, only in non-obese white women (p<0.01) with small effect size 
(slope 0.0022 g/cm2 per 10 mcg/dl change in serum iron). This relationship was not present 
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in obese subjects or in black women, though the slopes were not significantly different 
between white and black women. Thus in adjusted models, the negative univariate 
relationship of BMD to serum iron did not persist.
Neither C-terminal nor intact FGF23 were related significantly to BMD in any adjusted 
models (Supplemental Table 2), including models adjusting for iron and obesity in white and 
black women; and in models in white women adjusting for PTH, 25OHD and 1,25(OH)2D.
3.7 Longitudinal changes in iron and FGF23 in white women
Samples from two visits were analyzed from 338 white women, with a median interval of 
5.7 years between visits, to assess changes in biochemistries (Supplemental Table 3). The 
baseline age at the initial visit in this subset was 35.7 years (first quartile 30.8 years; third 
quartile 40.3 years). Changes in C-terminal FGF23 correlated inversely to changes in serum 
iron (r=−0.163, p <0.01) (Figure 4), but intact FGF23 changes did not relate to iron changes 
(Supplemental Figure 2).
4. Discussion
This study evaluated the relationship of iron to intact and C-terminal FGF23 in a large 
cohort of healthy premenopausal white and black women. Serum iron concentration was 
independently related to C-terminal FGF23 but was not related to intact FGF23, even after 
adjustment for several biochemical variables. Likewise changes in serum iron predicted 
changes in C-terminal FGF23 but not intact FGF23 over a median of 5.7 years. The 
relationship of C-terminal FGF23 to iron varied with serum phosphorus (Supplemental 
Figure 1). Thus the highest C-terminal FGF23 concentrations occurred in subjects with the 
lowest serum iron regardless of phosphorus; while the lowest C-terminal FGF23 
concentrations occurred in those subjects with the highest serum iron and lowest serum 
phosphorus. Importantly, the increase in C-terminal FGF23 with lower iron concentrations 
was most pronounced in the iron deficient range, as evidenced by the steeper slope in this 
range.
This is consistent with previous reports that while low iron status increases gene expression 
of FGF23, FGF23 protein levels are further regulated by cleavage into inactive N- and C-
terminal fragments to maintain normal phosphate homeostasis (3, 4, 25, 26). Other authors 
have noted an inverse association of iron stores assessed by ferritin and hemoglobin to C-
terminal FGF23 in iron deficient Gambian children, with responsiveness of C-terminal 
FGF23 to treatment of iron deficiency(26, 27). In a small number of women, iron status was 
correlated inversely to C-terminal FGF23 (14). Recently iron levels were also noted to be 
inversely related to C-terminal FGF23 in elderly patients (28). However these authors also 
found an inverse relationship between serum iron and intact FGF23 concentrations, using the 
Immutopics intact FGF23 ELISA. Differences from the present study may be due to assay 
differences or to population differences. Although males were not included in the current 
study, intact FGF23 using the Kainos assay did not correlate to serum iron in a small number 
of healthy non-elderly males (6).
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Serum iron was lower in black than white women, and more black women were iron 
deficient. The median C-terminal FGF23 did not differ between white and black women, but 
the distribution was positively skewed in both groups, and the inverse relationship between 
C-terminal FGF23 and serum iron was similar. C-terminal FGF23 correlated with intact 
FGF23 in white women but not black women. The differences between black and white 
women for relationships of intact FGF23 with C-terminal FGF23 (or for relationships 
between FGF23 and other variables) are unexplained. In part these findings may be due to 
the smaller sample size and an increased incidence of iron deficiency in black women, since 
iron deficiency influences the amount of C-terminal FGF23.
Intact FGF23 was positively and similarly associated with phosphorus in both groups (black 
women r=0.163; white women r=0.120, each p<0.01). Although the ratio of intact to C-
terminal FGF23 was similar between groups, the C-terminal FGF23 was related to serum 
phosphorus in black women but not in white women. However, black women had slightly, 
but significantly, lower intact FGF23 with slightly higher serum phosphorus than white 
women (each p<0.01), suggesting a possible racial difference in the regulation of serum 
phosphorus concentration. In addition, only intact FGF23 was related to 1,25(OH)2D 
(measured in white women). However, C-terminal FGF23 was influenced by serum iron in 
both white and black women. Overall, these data are biologically consistent with the intact 
FGF23 being the functional protein in regards to regulating phosphorus metabolism. Thus 
measurements of intact FGF23 are more likely to provide biologically important information 
regarding phosphorus metabolism.
Phosphorus was inversely related to iron concentrations, but intact FGF23 is not affected by 
serum iron concentrations in the absence of mutations of FGF23 impairing cleavage(3, 4). 
One possible explanation for this finding is that high dietary iron intake could serve as a 
phosphate binder, inhibiting intestinal phosphate absorption. Indeed oral iron has been 
administered as a phosphate binder in chronic kidney disease patients(29).
Although BMD was inversely associated with serum iron at the spine in white women and 
femur neck in black women on univariate analysis, a biologically important systemic factor 
such as iron is not likely to have important effects only at different BMD sites in different 
race groups. Furthermore these small inverse correlations were eliminated (or reversed on 
one subgroup) when adjusting for other variables, especially weight. In adjusted analyses, 
BMD also did not correlate to intact or C-terminal FGF23 in white or black premenopausal 
women. Consequently there does not appear to be a direct impact of FGF23 concentrations 
on BMD within the ranges experienced in normal healthy premenopausal women.
Strengths of this study include the large sample size and the inclusion of both white and 
black premenopausal women, along with the assessment of both intact and C-terminal 
FGF23 and BMD. In addition this was also the first study to demonstrate longitudinally that 
changes in serum iron correlate to changes in C-terminal FGF23 in a large number of 
healthy premenopausal women, confirming the nature of relationship of C-terminal FGF23 
and iron.
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Limitations included that PTH, 25OHD and 1,25(OH)2D were only measured in white 
women and that serum iron and percent iron saturation were the only measures of iron 
status. Thus the models including PTH, 25OHD and 1,25(OH)2D are only generalizable to 
white women. The analysis also did not account for other measures of iron status such as 
ferritin or hemoglobin. However the inclusion of UIBC in models, which increases with iron 
deficiency and has been used as an indicator of iron status (23, 24), enables the models to 
account for iron binding capacity in assessing degree of iron deficiency. FGF23 was 
measured in serum rather than in plasma, and the C-terminal FGF23 concentrations were 
lower than previous reported ranges measured in plasma(3). Thus C-terminal FGF23 
concentrations cannot be directly compared to studies using plasma C-terminal FGF23. 
However, despite this difference in serum versus plasma C-terminal FGF23 concentrations, 
the present study demonstrated a similar though smaller relationship between serum iron and 
serum C-terminal FGF23 (r=−0.134 in white women and r=−0.188 in black women), to that 
previously reported between serum iron and plasma C-terminal FGF23 in white women (r=
−0.278) (3). In the previous study using plasma FGF23, we also could not identify a 
relationship between C-terminal FGF23 and serum phosphorus. These indicate some 
consistency of these relationships when using either plasma or serum C-terminal FGF23, 
even though the absolute values were smaller when measured in serum. On the other hand 
intact FGF23 concentrations in serum were similar to that previously reported in plasma 
from healthy subjects(3).
Studies investigating the influence of iron on BMD have predominantly focused on dietary 
iron intake (30–32), or on iron overload states (17, 33). Notably, iron restriction impairs 
calcium phosphate mineral accrual in female rats, which is exacerbated by concomitant 
calcium deficiency(34). Dietary iron intake may have a protective effect on bone loss at the 
spine(30), and is positively associated with BMD in adult women, especially among those 
receiving estrogen replacement therapy (31, 32).
Among Korean women under age 45 and among men, iron stores were not related to 
proximal femur BMD (18). These results are similar to our femur neck BMD findings in 
premenopausal white women, though an inverse relationship with serum iron and femur 
neck BMD was present in black women. Our study indicated a small inverse relationship of 
iron to spine BMD in white women, but in adjusted models BMD was no longer inversely 
related to iron and instead had a small positive relationship at the femur neck (only in non-
obese white women). Conversely, prevalent osteoporosis and fractures were 1.55-fold higher 
in postmenopausal women with high versus low iron stores (18), and high iron stores 
associated with declines in proximal femur BMD in Korean postmenopausal women and 
middle aged men(19).
Low BMD occurs with elevated risk of vertebral fractures in iron excess states due to genetic 
hemochromatosis (17, 33) or treatment of beta-thalassemia (35). Low BMD occurs in these 
conditions even in the absence of complications such as hypogonadism or cirrhosis, which 
may independently contribute to risk. BMD in beta-thalassemia improves after iron 
chelation therapy (35). However, in our study few women had high serum iron 
concentration, limiting the ability to assess iron overload.
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Previous studies report conflicting data regarding the relationship of BMD to FGF23. Using 
various unadjusted or adjusted models, a positive association has been reported between 
spine BMD or hip BMD and either C-terminal FGF23 or intact FGF23 in older men(11, 12) 
and postmenopausal women(10, 14). However some studies indicate no relationship between 
BMD and C-terminal FGF23 in women(11), or between BMD and intact FGF23 in men(13). 
We found no significant relationship between BMD and intact (or C-terminal) FGF23 in 
either white women or black women, using unadjusted and adjusted models.
In one study, older men with the highest intact FGF23 concentrations also had increased 
fracture risk independent of BMD (36), but other authors found that intact FGF23 increased 
fracture risk only in men with chronic kidney disease(13). Our study did not assess fracture 
risk, but the absence of effect of FGF23 on BMD would decrease the likelihood of effects on 
fracture risk in premenopausal women.
Of the measured variables, BMD was most strongly correlated to weight (positively) in both 
groups. In contrast, iron was inversely associated with weight. Both C-terminal FGF23 and 
intact FGF23 positively associated with obesity in other studies (14, 37, 38), and the 
inclusion of body mass index in an adjusted model abolished a positive univariate 
relationship of BMD with C-terminal FGF23 in women (14). We also demonstrated a 
positive association between body weight and intact FGF23 in premenopausal black and 
white women. However, C-terminal FGF23 was negatively associated with weight in black 
women, with no association in white women. After inclusion of weight in adjusted models, 
BMD was not related to iron, intact FGF23 or C-terminal FGF23, except for a slight positive 
femur neck BMD relationship with iron in the subgroup of non-obese white women. 
However, the relationship of iron to C-terminal FGF23 was robust and did persist after 
weight adjustment.
In conclusion, in a large sample of healthy premenopausal white and black women, serum 
iron concentrations were inversely related to C-terminal FGF23, especially at low iron 
concentrations, without relationship to intact FGF23. Changes of serum iron concentration 
over time were also inversely related to changes in serum C-terminal FGF23, but not intact 
FGF23. However, BMD was not significantly associated with serum iron, C-terminal FGF23 
or intact FGF23 concentrations in adjusted models. Thus it appears that neither iron, C-
terminal FGF23 nor intact FGF23 have significant effects on BMD at the levels generally 
experienced in healthy premenopausal women.
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Highlights
• Serum iron correlated negatively with C-terminal FGF23.
• Serum iron did not correlate with intact FGF23.
• In adjusted models BMD was not consistently related to intact FGF23, C-
terminal FGF23 or iron.
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Figure 1. 
The relationships of serum intact FGF23 (panel A and B) and C-terminal FGF23 (panel C 
and D) concentrations to serum iron concentration are shown for black women (panels A 
and C) and white women (panel B and D). The solid line indicates the linear relationship. 
The dashed line is a curve fitted to the datapoints, which in panel C and D indicates an 
apparent change-point at an iron level of approximately 50 mcg/dl, with the slope of a fitted 
line for C- terminal FGF23 becoming steeper at iron concentrations below 50 mcg/dl. 
Significance is set at p<0.01.
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Figure 2. 
The relationships of BMD at the femur neck (A and B) and the lumbar spine (C and D) to 
serum iron concentration are shown for black women (A and C) and white women (B and 
D). Significance is set at p<0.01.
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Figure 3. 
FGF23 and BMD. Intact FGF23 concentrations (A, B, E, F) and C-terminal FGF23 
concentrations (C, D, G, H) are plotted on the x-axis with femur neck BMD (A–D) and 
spine BMD (E–H) on the y-axis. Significance is set at p<0.01. There were no significant 
relationships.
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Figure 4. 
The relationship of changes in serum iron concentration over a median interval of 5.7 years 
to changes in serum C-terminal FGF23 (panel A) and intact FGF23 (panel B) concentrations 
are plotted in white women. Δ indicates the change in the value of the variable. Significance 
is set at p<0.01.
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